Clinical Trial Update: Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update on nivolumab with stereotactic ablative radiation (SAbR) in metastatic clear cell renal cell carcinoma; the study is terminated with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2022-08-08